LearnGlossaryMarketStocksSuperinvestorsSign in

FLGT

Fulgent Genetics, Inc.

Healthcare · $625M market cap

Verdict

We can't put a fair value on FLGT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth42.5% a year✓
Sales growth-2.0% a year✗
Free cash flow growth91.5% a year✓
Return on invested capital-9.8%✗

Follow FLGT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases, 2 sales worth $75K and 2 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Xie Jian

President and COO · 2026-09-02

Sold

$42K

Gao Hanlin

Chief Scientific Officer · 2026-09-02

Sold

$33K

Other filings

Hsieh Ming

Chief Executive Officer · 2026-09-01

Tax withholding

$86K

Kim Paul

CFO and Treasurer · 2026-09-01

Tax withholding

$41K

About Fulgent Genetics, Inc.

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited…

Medical - Diagnostics & Research

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works